AcouSort has been selected by the European Innovation Council (EIC) for participation in the European Pavilion at BIO 2024 in San Diego, USA, after a competitive evaluation process. AcouSort is thereby one of only 15 European companies selected by the EU for full sponsorship at America’s leading medical trade fair, taking place in San Diego June 3-6. AcouSort has also been invited to participate in ISCT in Vancouver where the company will showcase its innovative solutions.

During the convention in San Diego, AcouSort will mainly focus on partnering and 1-on-1 meetings, discussing future OEM solutions within both point-of-care diagnostics and cell therapy. As BIO 2024 attracts 20,000+ biotechnology and pharma leaders, thereby offering a fantastic opportunity to identify new opportunities and promising partnerships.

The 2024 BIO International Convention will feature more than 100 interactive sessions across four days covering business development, a variety of diagnostic areas as well as next generation biotherapeutics. The participants in the delegation of the European Pavilion were selected based on their internationalization goals, technological fit with the scope of the trade fair, as well as their capacity to create business out of their participation.

Prior to the convention in San Diego, AcouSort will also participate as part of the Innovation Zone in ISCT 2024 in Vancouver where the company will be showcasing its innovative solutions for automated sample preparation for cell therapy. This well renowned event offers a great opportunity for the company to connect with global scientists, experts and potential customers, making it an ideal platform for AcouSort to continue developing its networking in the field of cell therapy.

“It is with great pride we are going to San Diego as one of only 15 European SMEs or startups selected by EIC for participation at BIO 2024. This is one of the most important conferences in the healthcare and biotech industry, where most leading companies are represented. We are equally excited to participate in the Innovation Zone of ISCT 2024 in Vancouver, which will provide us with a great opportunity to keep extending our reach within the rapidly evolving cell therapy space,” says AcouSort’s CEO Torsten Freltoft.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Carnegie Investment Bank AB (publ).